BioStock: Prolight Diagnostics CSO comments on latest data
Supported by the latest data from its Psyros point-of-care system, Prolight Diagnostics is ready to initiate pre-validation trials using fresh whole blood and banked plasma patient samples to measure troponin.– The lower the detection limit of the system, the more accurately it can measure troponin at the relevant concentrations. This is where Psyros single-molecule counting system has a strong competitive advantage, says Prolight Diagnostics’ CSO Aileen McGettrick.Read the full article at biostock.se : https://www.biostock.se/en/2024/05/prolight-